Cardiovascular
Statins (HMG-CoA reductase inhibitors)
The main drugs for lowering LDL cholesterol; they substantially reduce coronary events and deaths from coronary heart disease.
Mécanisme d’action
- Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis, mainly in the liver.
- With less cholesterol made inside them, liver cells put more LDL receptors on their surface.
- The extra receptors take up LDL from the blood, so plasma LDL cholesterol falls; triglycerides fall too, and HDL may rise.
- Beyond lowering lipids, they stabilise plaques, improve endothelial function, reduce platelet thrombus formation and damp vascular inflammation.
Cibles moléculaires
- HMG-CoA reductase: Competitive inhibitor
Médicaments : Statins (HMG-CoA reductase inhibitors)
- Atorvastatin
- Rosuvastatin
- Simvastatin
- Pravastatin
- Lovastatin
- Fluvastatin
- Pitavastatin
Indications thérapeutiques
- First-line treatment for people at raised risk of atherosclerotic cardiovascular disease
- All types of hyperlipidaemia, though less effective in homozygous familial hypercholesterolaemia, where LDL receptors are missing
- Secondary prevention after myocardial infarction
Maladies traitées
Pharmacocinétique
- Rosuvastatin and atorvastatin lower LDL cholesterol the most.
- All except pravastatin are metabolised by cytochrome P450 in the liver; simvastatin by CYP3A4, so its inhibitors raise its levels.
Effets indésirables
- Raised liver enzymes
- Myopathy and, rarely, rhabdomyolysis; creatine kinase is checked if muscle symptoms appear
Contre-indications selon le terrain
- Pregnancy and breastfeeding (Contre-indiqué): Cholesterol synthesis is needed for the developing fetus.
- Liver cirrhosis (Avec précaution): Statins are cleared by the liver and can raise transaminases; they are contraindicated in active or decompensated liver disease.
Autres précautions et interactions
- Risk of rhabdomyolysis rises with renal impairment, hypothyroidism, older age and interacting drugs (azole antifungals, protease inhibitors, ciclosporin, erythromycin, gemfibrozil, niacin).
- May increase the effect of warfarin.
Sujets liés
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 22, Drugs for Hyperlipidemia, HMG CoA reductase inhibitors
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.